Gilead’s 2026 Forecast Falls Short of Investor Expectations (2)

Gilead Sciences Inc. forecast 2026 product revenue and profit that missed analysts’ expectations, even after it outperformed during last year’s fourth quarter.

The Foster City, California-based biotech company said it would generate full year drug sales of $29.6 billion to $30 billion, falling just short of the average estimate from analysts. Adjusted profits will be between $8.45 and $8.85 a share, it said in a statement, with a midpoint below the $8.76 a share average estimate from analysts.

The company could achieve $800 million in sales in 2026 for its new long-acting HIV prevention drug Yeztugo, said Chief Executive Officer ...